检索历史 清除

目的：探讨白介素17（IL-17）对人结肠癌细胞株SW480和LOVO细胞增殖、侵袭和迁移能力的作用，以及可能的机制。方法根据外源性人IL-17是否作用于人结肠癌细胞株SW480和LOVO，分为4组细胞：SW480对照组（SW480细胞）、LOVO对照组（LOVO细胞）、SW480实验组（50μg／L IL-17处理SW480细胞）和LOVO实验组（50μg／L IL-17处理LOVO细胞）。CCK-8法检测各组细胞增殖活性，细胞增殖率（％）＝[（A 实验组-A 空白组）／（A 对照组-A 空白组）]×100％；Transwell实验检测各组细胞侵袭和迁移能力，实时定量聚合酶链反应（real time-PCR）检测各组细胞血管内皮生长因子（VEGF）、基质金属蛋白酶9（MMP-9）mRNA的表达，蛋白质印迹（western blot）检测各组细胞信号传导与转录激活因子3（STAT3）、磷酸化STAT3（p-STAT3）、VEGF和MMP-9蛋白的表达，酶联免疫吸附法（ELISA）检测各组细胞上清液中VEGF、MMP-9蛋白的含量。结果培养24 h、48 h和72 h后，实验组SW480细胞的增殖率分别为1．18％±0．07％、1．42％±0．09％和1．62％±0．08％， LOVO细胞的增殖率分别为1．13％±0．02％、1．32％±0．05％和1．73％±0．02％。 Transwell实验显示， IL-17作用24 h 后，SW480实验组和 LOVO 实验组侵袭细胞个数分别为34．00±0．45和41．60±0．51，多于对照组（分别为4．53±0．14和3．67±0．33），差异有统计学意义（SW480：t＝-76．026，P＝0．001；LOVO：t＝-81．580，P＝0．005）；SW480实验组和LOVO实验组迁移细胞个数分别为36．40±0．51和46．40±0．68，多于对照组（分别为7．83±0．69和6．67±0．48），差异有统计学意义（SW480：t＝-51．542， P ＝0．003；LOVO：t ＝-49．265，P ＝0．005）。实时定量聚合酶链反应结果显示，IL-17作用24 h后， SW480实验组细胞VEGF、MMP-9 mRNA相对表达量分别为1．53±0．12和2．44±0．23，高于SW480对照组（均为1.00），差异均有统计学意义（VEGF：t＝3．211，P＝0．027；MMP-9：t＝4．306，P＝0．025）；LOVO实验组细胞VEGF、MMP-9 mRNA相对表达量分别为2．96±0．35和3．38±0．55，高于LOVO对照组（均为1.00），差异均有统计学意义（VEGF：t＝3．799，P ＝0．043；MMP-9：t＝5．254，P ＝0．039）。Western blot实验表明，IL-17作用24 h后，SW480实验组STAT3、p-STAT3、VEGF和MMP-9蛋白的相对表达量明显高于对照组（STAT3：t＝3．233，P ＝0．023；p-STAT3：t＝3．954，P ＝0．032；VEGF：t ＝3．201，P ＝0．025；MMP-9：t＝3．154，P ＝0．029）；LOVO实验组STAT3、p-STAT3、VEGF和MMP-9蛋白的相对表达量明显高于对照组（STAT3：t＝3．788，P＝0．012；p-STAT3：t＝2．662，P＝0．040；VEGF：t＝4．118， P ＝0．035；MMP-9：t＝4．268， P ＝0．030）。 ELISA实验结果显示， SW480细胞实验组上清液中VEGF和MMP-9的含量分别为5491．41±63．22和21．43±1．35，均高于对照组（分别为4456．32±87．56和18．57±2．44），差异具有统计学意义（VEGF：t＝6．993，P ＝0．037；MMP-9：t＝5．587， P ＝0．040）。 LOVO细胞实验组VEGF和MMP-9的含量分别为8631．46±129．59和178．32±3．20，亦高于对照组（分别为8122．38±108．66和163．22±6．89），差异具有统计学意义（VEGF：t＝7．013， P ＝0．044； MMP-9：t＝6．762， P ＝0．043）。结论 IL-17能上调SW480和LOVO人结肠癌细胞中STAT3和p-STAT3蛋白的表达，激活STAT3信号转导通路，从而上调VEGF和MMP-9蛋白的表达，增强SW480和LOVO结肠癌细胞的侵袭和迁移能力。

Objective To investigate the effect and its possible mechanism of interleukin-17 (IL-17) on invasion and metastasis of human colon cancer cells. Methods IL-17 was added into the culture media of human colon cancer cells SW480 and LOVO. Cells were divided into 4 groups: SW480 control group (SW480 cells), LOVO control group (LOVO cells), SW480 experiment group (50 μg/ L IL-17+SW480 cells), and LOVO experiment group (50 μg/L IL-17+LOVO cells). Cell growth was measured by CCK-8 assay. The proliferation rate (%) =[(Aexperiment group-Ablank)/(Acontrol group-Ablank)] ×100%). The ability of cell invasion and migration was measured by transwell assay. Real time-PCR was used to detect mRNA expression of VEGF and MMP-9. Western blot was performed to detect protein expression of STAT3, p-STAT3, VEGF and MMP-9. Enzyme-linked immunosorbent assay (ELISA) was applied to measure the protein content of VEGF and MMP-9 in the supernatant. Results After cultivation for 24, 48 and 72 hours, CCK-8 assay revealed that the proliferation rate of SW480 was 1.18%± 0.07%, 1.42%± 0.09%, and 1.62%± 0.08%; the proliferation rate of LOVO was 1.13% ± 0.02%, 1.32%± 0.05% and 1.73%±0.02% in experiment group. Transwell experiments showed that after cultivation with IL-17 for 24 hours, number of invasion cell in experimental groups (SW480:34.00 ± 0.45, LOVO: 41.60 ± 0.51) was higher as compared to corresponding control groups (SW480:4.53 ± 0.14; LOVO: 3.67 ± 0.33) with significant differences (SW480: t = -76.026, P = 0.001;LOVO: t=-81.580, P=0.005). The number of migration cell in experimental groups (SW480:36.40 ± 0.51, LOVO: 46.40 ± 0.68) was higher as compared to corresponding control groups (SW480: 7.83 ± 0.69;LOVO:6.67 ± 0.48) with significant differences (SW480:t=-51.542, P= 0.003;LOVO:t=-49.265, P=0.005). Real-time PCR results revealed that after cultivation with IL-17 for 24 hours , VEGF and MMP-9 mRNA relative expression levels in experimental groups (SW480: VEGF:1.53 ± 0.12, MMP-9: 2.44 ± 0.23; LOVO: VEGF: 2.96 ± 0.35, MMP-9: 3.38 ± 0.55) were higher than those in control groups (both 1) with significant differences (VEGF: t=3.799, P=0.043; MMP-9:t=5.254, P=0.039). Western blot illustrated that after cultivation with IL-17 for 24 hours, STAT3, p-STAT3, VEGF and MMP-9 proteins relative expression levels in experimental groups were significantly higher that those in control groups (SW480:STAT3:t=3.233, P=0.023;p-STAT3:t=3.954, P=0.032;VEGF: t=3.201, P=0.025; MMP-9: t=3.154, P=0.029; LOVO: STAT3: t=3.788, P=0.012;p-STAT3: t=2.662, P=0.040; VEGF: t=4.118, P=0.035; MMP-9: t=4.268, P=0.030). ELISA indicated that content of VEGF and MMP-9 in the supernatant of experimental groups (SW480: VEGF 5 491.41 ± 63.22, MMP-9: 21.43 ± 1.35. LOVO: VEGF: 8 631.46 ± 129.59, MMP-9: 178.32 ± 3.20) were higher than those in control groups (SW480: VEGF:4 456.32 ± 87.56, MMP-9:18.57 ± 2.44. LOVO: VEGF: 8 122.38 ± 108.66, MMP-9: 163.22 ± 6.89) with significant differences (SW480:VEGF: t=6.993,P=0.037; MMP-9: t=5.587, P=0.040. LOVO: VEGF: t=7.013, P=0.044;MMP-9: t=6.762, P=0.043). Conclusion IL-17 may be able to activate STAT3 signal transduction pathway in vitro through up-regulation of VEGF and MMP-9 expression , thereby enhancing the invasion and migration of colon cancer SW480 and LOVO cells.